Technohal

dr. M.M.A. Kip (Michelle)

Assistant Professor
BMS-TPS-HTSR
Technohal 3101
m.m.a.kip@utwente.nl
+31534896646
Business card

Dr. Michelle Kip has received her PhD (cum laude) from the University of Twente, Enschede, the Netherlands, in April 2018. Her thesis was entitled: "Early Health Technology Assessment of Point-of-Care and Laboratory Diagnostics". Currently, she works as a postdoctoral researcher at the Health Technology & Services Research Department at the University of Twente. She is experienced in the field of (early) Health Technology Assessment, and her research focuses on methods to evaluate the health economic impact of medical technologies in several phases of development, using cost-effectiveness analysis and simulation modeling. Besides evaluating the health economic impact of medical technologies, she is also experienced in the field of Multi-Criteria Decision Analysis, which includes methods to evaluate stakeholders’ preferences with regard to (new) medical technologies, as well as in expert elicitation.

During her postdoc, Michelle will work on the UCAN CAN-DU project, which aims to develop a biomarker based predictive testing approach to optimize clinical management in juvenile idiopathic arthritis compared to current standard of practice. Within this project, she will be involved in quantifying the impact of (personalized treatment strategies for) juvenile idiopathic arthritis in terms of costs and health outcomes.

Expertise

  • Medicine and Dentistry

    • Patient
    • Health Care Cost
    • Diagnosis
    • Laboratory
    • Child
    • Cost-Effectiveness Analysis
    • General Practitioner

  • Nursing and Health Professions

    • Juvenile Rheumatoid Arthritis

Organisations

Publications

2024

Validating Health Economic Models With the Probabilistic Analysis Check dashBOARD (2024)Value in health, 27(8), 1073-1084. Pouwels, X. G. L. V., Kroeze, K., van der Linden, N., Kip, M. M. A. & Koffijberg, H.https://doi.org/10.1016/j.jval.2024.04.008Development of a decision support tool for biologic therapy withdrawal decisions in non-systemic juvenile idiopathic arthritis (2024)Medical decision making, 44(2), NP53-NP55. van Til, J. A., Kip, M. M. A., Marinescu-Muster, R., Groothuis-Oudshoorn, C. G. M., Currie, G., Benseler, S., Swart, J., Vastert, S., Wulffraat, N., Yeung, R., Marshall, D. & IJzerman, M. J.https://doi.org/10.1177/0272989X231225267

2023

Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis (2023)Rheumatology (E-pub ahead of print/First online). Florax, A. A., Doeleman, M. J. H., de Roock, S., van der Linden, N., Schatorjé, E., Currie, G., Marshall, D. A., IJzerman, M. J., Yeung, R. S. M., Benseler, S. M., Vastert, S. J., Wulffraat, N. M., Swart, J. F. & Kip, M. M. A.https://doi.org/10.1093/rheumatology/kead688Managing juvenile idiopathic arthritis within the context of their life: What we learnt from children and youth living with juvenile idiopathic arthritis and their parents (2023)Musculoskeletal care, 21(4), 1248-1260. Currie, G. R., Kennedy, B. L., Benseler, S. M., R. S. M., Y., Swart, J. F., Vastert, S. J., Wulffraat, N. M., M. M. A., K., MacKean, G. & Marshall, D. A.https://doi.org/10.1002/msc.1805Two point-of-care test-based approaches for the exclusion of deep vein thrombosis in general practice: a cost-effectiveness analysis (2023)BMC Primary Care, 24(1). Article 42. Heerink, J. S., Nies, J., Koffijberg, H., Oudega, R., Kip, M. M. A. & Kusters, R.https://doi.org/10.1186/s12875-023-01992-zWithdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? (2023)Pediatric Rheumatology, 21(1), 69. Article 69. van Til, J. A., Kip, M. M. A., Schatorjé, E. J. H., Currie, G., Twilt, M., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N., Yeung, R. S. M., Groothuis-Oudshoorn, C. G. M. K., Warta, S., Marshall, D. A. & IJzerman, M. J.https://doi.org/10.1186/s12969-023-00845-4What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey (2023)Clinical rheumatology, 42(8), 2173-2180. Currie, G. R., Groothuis-Oudshoorn, C. G. M., Twilt, M., Kip, M. M. A., IJzerman, M. J., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R. & Marshall, D. A.https://doi.org/10.1007/s10067-023-06616-6Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: A real-world data analysis (2023)Rheumatology, 62(SI2), SI170-SI180. Kip, M. M. A., de Roock, S., Currie, G., Marshall, D. A., Grazziotin, L. R., Twilt, M., Yeung, R. S. M., Benseler, S. M., Vastert, S. J., Wulffraat, N., Swart, J. F. & IJzerman, M. J.https://doi.org/10.1093/rheumatology/keac299

2022

As open as possible, as closed as necessary: how to find the right balance in sharing citizen science data for health? (2022)Proceedings of Science, 418. Article 028. Wolkorte, R., Heesink, L. & Kip, M. M. A.https://pos.sissa.it/418/028/pdfFactors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis (2022)Pediatric Rheumatology, 20(1), 1-12. Article 51. Grazziotin, L. R., Currie, G., Twilt, M., IJzerman, M. J., Kip, M. M. A., Koffijberg, H., Bonsel, G., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R. S. M., Armbrust, W., van den Berg, J. M. & Marshall, D. A.https://doi.org/10.1186/s12969-022-00713-7

Research profiles

Courses academic year 2024/2025

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

Courses academic year 2023/2024

Address

University of Twente

Technohal (building no. 18), room 3101
Hallenweg 5
7522 NH Enschede
Netherlands

Navigate to location

Organisations

Scan the QR code or
Download vCard